Gene K Ma1, David S Goldberg1, Nikhil Thiruvengadam2, Vinay Chandrasekhara1, Michael L Kochman1, Gregory G Ginsberg1, Charles M Vollmer3, Nuzhat A Ahmad4. 1. Gastroenterology Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 2. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 3. Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 4. Gastroenterology Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Electronic address: nuzhat.ahmad@uphs.upenn.edu.
Abstract
BACKGROUND: In 2015, the American Gastroenterological Association (AGA) published guidelines to provide recommendations for management of suspected pancreatic cystic neoplasms (PCNs). The aim of this study was to compare efficacy of these with the Fukuoka consensus guidelines in predicting advanced neoplasia (AN) in patients with suspected PCNs. STUDY DESIGN: We performed a retrospective study of 239 patients who underwent surgical resection for suspected mucinous PCN at a tertiary care center from 2000 to 2014. Surgical pathology was the gold standard. The AGA and Fukuoka criteria were applied, and their performance in predicting AN, defined as invasive cancer or high-grade dysplasia (HGD), was assessed. RESULTS: Advanced neoplasia was found in 71 of 239 (29.7%) patients (28 invasive cancer, 43 HGD). The Fukuoka "high-risk" (FG-HR) and AGA "high-risk" (AGA-HR) criteria identified patients with AN with sensitivities of 28.2% and 35.2%, specificities of 95.8% and 94.0%, positive predictive values of 74.1% and 71.4%, and negative predictive values of 75.9% and 77.5%, respectively. Overall, there was no significant difference between the guidelines for prediction of AN. There were 7 and 6 cases with invasive cancer, and 23 and 24 cases with HGD missed by the FG-HR and AGA-HR guidelines, respectively. CONCLUSIONS: In a retrospective analysis, the AGA guidelines are not superior to the Fukuoka guidelines in identifying AN in suspected PCNs. Both sets of guidelines have fair PPV for detection of AN, which would lead to avoidable resections in patients without AN. Additionally, the high-risk features of both guidelines do not accurately identify all patients with AN.
BACKGROUND: In 2015, the American Gastroenterological Association (AGA) published guidelines to provide recommendations for management of suspected pancreatic cystic neoplasms (PCNs). The aim of this study was to compare efficacy of these with the Fukuoka consensus guidelines in predicting advanced neoplasia (AN) in patients with suspected PCNs. STUDY DESIGN: We performed a retrospective study of 239 patients who underwent surgical resection for suspected mucinous PCN at a tertiary care center from 2000 to 2014. Surgical pathology was the gold standard. The AGA and Fukuoka criteria were applied, and their performance in predicting AN, defined as invasive cancer or high-grade dysplasia (HGD), was assessed. RESULTS: Advanced neoplasia was found in 71 of 239 (29.7%) patients (28 invasive cancer, 43 HGD). The Fukuoka "high-risk" (FG-HR) and AGA "high-risk" (AGA-HR) criteria identified patients with AN with sensitivities of 28.2% and 35.2%, specificities of 95.8% and 94.0%, positive predictive values of 74.1% and 71.4%, and negative predictive values of 75.9% and 77.5%, respectively. Overall, there was no significant difference between the guidelines for prediction of AN. There were 7 and 6 cases with invasive cancer, and 23 and 24 cases with HGD missed by the FG-HR and AGA-HR guidelines, respectively. CONCLUSIONS: In a retrospective analysis, the AGA guidelines are not superior to the Fukuoka guidelines in identifying AN in suspected PCNs. Both sets of guidelines have fair PPV for detection of AN, which would lead to avoidable resections in patients without AN. Additionally, the high-risk features of both guidelines do not accurately identify all patients with AN.
Authors: Ajay V Maker; Vincent Hu; Shrihari S Kadkol; Lenny Hong; William Brugge; Jordan Winter; Charles J Yeo; Thilo Hackert; Markus Büchler; Rita T Lawlor; Roberto Salvia; Aldo Scarpa; Claudio Bassi; Stefan Green Journal: J Am Coll Surg Date: 2019-02-19 Impact factor: 6.113
Authors: Caitlin A McIntyre; Alessandra Pulvirenti; Sharon A Lawrence; Kenneth Seier; Mithat Gonen; Vinod P Balachandran; T Peter Kingham; Michael I DʼAngelica; Jeffrey A Drebin; William R Jarnagin; Peter J Allen Journal: Pancreas Date: 2019-07 Impact factor: 3.327
Authors: David S Weinberg; Constantine Gatsonis; Herbert J Zeh; Ruth C Carlos; Peter J O'Dwyer Journal: Contemp Clin Trials Date: 2020-09-10 Impact factor: 2.226